share_log

Avivagen Inc. (OTCMKTS:VIVXF) Sees Significant Drop in Short Interest

Financial News Live ·  Oct 27, 2022 10:14

Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totalling 2,800 shares, a drop of 64.6% from the September 30th total of 7,900 shares. Based on an average daily volume of 15,900 shares, the days-to-cover ratio is presently 0.2 days.

Avivagen Price Performance

OTCMKTS:VIVXF opened at $0.10 on Thursday. Avivagen has a twelve month low of $0.10 and a twelve month high of $0.38. The stock's 50 day moving average price is $0.12 and its two-hundred day moving average price is $0.14.

Get Avivagen alerts:

Avivagen (OTCMKTS:VIVXF – Get Rating) last posted its quarterly earnings results on Friday, September 16th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.23 million. Sell-side analysts anticipate that Avivagen will post -0.08 EPS for the current fiscal year.

Avivagen Company Profile

(Get Rating)

Avivagen Inc, a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.

See Also

  • Get a free copy of the StockNews.com research report on Avivagen (VIVXF)
  • Be Sure You Own United Parcel Service for the Right Reasons
  • 3 Roughed-Up Dividend Aristocrats with Good Long-Term Prospects
  • Sell-Siders See Value in Highly Valued Chipotle Stock
  • Strong Fundamentals Make Bristol Myers Squibb Stock a Real Value
  • General Electric May be a Buy in the Right Portfolio

Receive News & Ratings for Avivagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avivagen and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment